The application of artificial intelligence in healthcare practice: A mapping review of systematic reviews.

Artif Intell MedJul 18, 2026 (epub)
Clinical ResearchOncology (Medical)Radiology (Diagnostic)

Adam Andersen, Ruiping Huang, Edward Jiusi Liu

✦ AI-curated · Sources linked

In 30 seconds

This systematic review mapped 368 systematic reviews on artificial intelligence (AI) applications in healthcare, published from 2019 to February 2026. The study found that over 80% of AI applications focused on diagnosis, prognosis, and treatment, with a notable increase in ethical concerns reported in 78.5% of reviews. The findings highlight the expanding role of AI in clinical practice.

Key findings

  • AI applications in healthcare are concentrated in radiology, oncology, and critical care.
  • 68% of training data sources were from diagnostic imaging, EHR data, and biomarkers.
  • Ethical concerns were reported in 78.5% of reviews, increasing from 2021 to 2025.
  • Newer data types, such as wearable device data, emerged from 2022 onward.

Why it matters

Understanding the landscape of AI applications in healthcare is crucial for clinicians to navigate the evolving technologies that can enhance patient care. Awareness of ethical concerns is also essential for responsible implementation.

Source

PubMed · PMID 42492159

Published in Artif Intell Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.